Maintained Buy: RAPP analyst rating on Rapport Therapeutics, Inc. Common Stock Mar 2026
BTIG and Cowen each maintained a Buy rating on Rapport Therapeutics, Inc. Common Stock (RAPP) on March 9, 2026. The RAPP analyst rating stayed bullish despite recent trial readouts and a new collaboration announcement. BTIG stressed that the X-TOLE2 readout offers “no readthrough,” while Cowen called the Tenacia collaboration “a prudent move.” We report the actions, analyst reasoning, and market implications based on the March 9, 2026 notes and real-time coverage.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
